EU Approval of Humira Biosimilar, ABP501, to Treat Adults and Children with IBD Favored

EU Approval of Humira Biosimilar, ABP501, to Treat Adults and Children with IBD Favored
ABP501, a biosimilar of Humira (adalimumab), was recommended for approval in the European Union to treat adults and some children with various inflammatory diseases, including inflammatory bowel disease (IBD), by the Committee for Medicinal Products for Human Use (CHMP). CHMP, an arm of the European Medicines Agency (EMA), issued its positive opinion for ABP 501 as a treatment for adults

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *